Santhera’s Agamree (vamorolone) Receives EC’s Approval to Treat Duchenne Muscular Dystrophy
Shots:
- Followed by the positive opinion from the CHMP, the EC has granted approval to the Santhera’s Agamree (dosing b/w 2 and 6mg/kg/day, for total of 30mos.) for the treatment of DMD patients (aged 4yrs. & +) based on results from the (VISION-DMD) and 3 other trials
- The results showed that Agamree neither reduced bone metabolism nor bone mineralization in the spine after 48wks. and recovered growth & bone health after switching from prednisone. Further data is being collected for its efficacy and safety
- Additionally, Catalyst Pharmaceuticals holds an exclusive license for Agarmee in North America & expects the US launch in Q1’24. Santhera anticipates the drug’s launch in Germany during Q1’24
Ref: Santhera | Image: Santhera
Related News:- Santhera’s Agamree (vamorolone) Receives the US FDA’s Approval for the Treatment of Duchenne Muscular Dystrophy (DMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
